bluuebunny/crossref_metadata_2025_split huggingface dataset:
First Metatarsophalangeal Arthrodesis Outcomes of Hallux Rigidus vs Hallux Valgus
Authors: Roth Warren J. , Hoch Caroline P. , Gross Christopher E. , Scott Daniel J. 
Published: November 2022

Category: Midfoot/Forefoot; Other Introduction/Purpose: First metatarsophalangeal (MTP) joint arthrodesis is a commonly performed surgical procedure for patients with hallux rigidus (HR) or severe hallux valgus (HV). The purpose of this study was to compare patient outcomes of 1st MTP arthrodesis between HR and HV cohorts. We hypothesized that there would be no difference in patient-reported outcome measures (PROMs) or complication rates between groups. Methods: A retrospective review was conducted at a single academic medical center of patients who underwent 1st MTP arthrodesis with one of two fellowship-trained foot and ankle orthopaedic surgeons between 2009 and 2021. A total of 136 patients (148 feet: HR=75, HV=47, both=44) met the inclusion criteria of the three-month follow-up minimum. Data collection included PROMs (i.e., Visual Analogue Scale [VAS], 12-item Short Form Survey [SF-12], Foot and Ankle Outcome Score [FAOS], and Foot and Ankle Ability Measure [FAAM], Patient-Reported Outcomes Measurement Information System [PROMIS]), radiographic markers, and complication and reoperation rates. The VAS, SF-12, FAOS, and FAAM were collected preoperatively; the FAOS and FAAM were collected postoperatively; and all were collected via prospective phone interview. Forty-six patients (50 feet: HR=21, HV=15, both=14) completed the phone interview at an average of 3.04 (range, 0.58-10.01) years postoperatively. Mean clinical follow-up was 1.25 (range, 0.25-6.14) years. Results: The HR had a significantly smaller improvement in HVA (HR=-3.60, HV=-17.44, combined=-15.27; p<.001), IMA (HR=- 0.16, HV=-2.80, combined=-2.55; p<.001), and 1st-5th metatarsal width (HR=-0.98, HV=-4.59, combined=-4.60; p<.001). There was a trend toward improved PROMs, although only significant for all groups with the VAS (p<.001, p<.001, p<.001), FAOS Quality of Life (p<.001, p=.030, p=.001), and FAAM Activities of Daily Living (p<.001, p=.046, p=.002) and Total (p=.001, p=.024, p=.016) scores. The HV group significantly improved among the least PROMs. (Table 1) Complication (HR=28.07%, HV=38.30%, combined=36.36%; p=.499) and reoperation (HR=14.04%, HV=25.53%, combined=20.45%; p=.334) rates did not differ by group, although both were lowest for the HR group. Superficial infection (HR=12.28%, HV=17.02%, combined=9.09%; p=.521) and nonunion (HR=17.54%, HV=10.64%, combined=13.64%; p=.599) rates also did not differ. Conclusion: Indication for MTP arthrodesis does not appear to influence subjective outcomes of 1st MTP arthrodesis, as only one postoperative PROM differed between cohorts. All groups trended toward PROM improvements at 1-year and 3-years postoperative, although the HR group was the only group to continue improving from 1-year to 3-years postoperative. Thus, this study begins to provide insight into the role that specific forefoot pathology plays in 1st MTP arthrodesis outcomes, as we only found radiographic measures to be significantly different.
Hallux Valgus with Increased DMAA Correction by Modified Lapidus Procedure
Authors: Shah Milaan A. , Stirling Briana E. , Gonzalez Tyler A. , Jackson J. Benjamin 
Published: November 2022

Category: Bunion; Midfoot/Forefoot Introduction/Purpose: Hallux valgus is one of the most common deformities treated by orthopedic foot and ankle surgeons. Hallux valgus can frequently present with an increased distal metatarsal articular angle (DMAA), which may require correction in addition to treating the hallux valgus deformity. Many surgical procedures can correct hallux valgus with an increased DMAA with varying levels of success. Thus, we investigate the efficacy of the modified Lapidus procedure, a triplanar correction, in correcting the DMAA in hallux valgus surgery. Methods: A retrospective chart review was performed on patients who underwent the hallux valgus reconstruction with a modified Lapidus procedure between April 26th, 2018 and November 19th, 2020. Exclusion criteria included any patient undergoing hallux valgus correction not receiving a modified Lapidus procedure and patients with inadequate follow up. Hallux valgus angle (HVA), intermetatarsal angle (IMA) and DMAA were measured on pre-operative, immediate post-operative and at final follow up weight bearing radiographs. Results: The study included a total of 99 cases of modified Lapidus procedure for hallux valgus on 85 subjects with an average follow up of 5.4 months. On radiologic assessment, the average DMAA decreased from 17.72 +- 6.18 degrees pre-operatively to 9.19 +- 5.19 degrees immediately post-operatively (p < 0.0001) and 9.79 +- 4.62 degrees at the final follow up (p < 0.0001). The average HVA decreased from 31.34 +- 10.39 degrees pre-operatively to 13.34 +- 6.16 degrees immediately post-operatively (p < 0.0001) and 15.05 +- 7.43 degrees at final follow up (p < 0.0001). Lastly, the IMA decreased from 14.99 +- 3.82 pre-operatively (p < 0.0001) to 4.66 +- 2.59 immediately post-operative and 6.62 +- 3.46 degrees at final follow up (p < 0.0001). The rate of recurrence was 3.03%. Conclusion: The modified Lapidus procedure is an effective procedure in correcting the HVA, IMA, and DMAA in hallux valgus surgery without the need for additional distal or proximal metatarsal osteotomies. Surgeons should consider this technique in patients with moderate to severe hallux valgus deformity who may require correction of their DMAA.
Impact of E-Scooter Injuries: A Systematic Review of 34 Studies
Authors: Singh Priya K. , Jami Meghana , Geller Joseph , Granger Caroline , Geaney Lauren E. , Aiyer Amiethab A. 
Published: November 2022

Category: Trauma; Ankle Introduction/Purpose: Due to the rapid expansion of scooter sharing companies in recent years, there has been a dramatic increase in the number of electric scooter injuries. The purpose of our study was to conduct a systematic review to characterize the demographics, most common injuries, and management of patients injured from electric scooters. Methods: This systematic review searched PubMed, EMBASE, Scopus, and Web of Sciences databases using variations of the terms 'motorized scooter', 'electric scooter', etc. Exclusion criteria included studies prior to 2015, study population less than 50, case reports, presentations or posters only, and studies focused on other devices. Two independent reviewers screened articles and data was analyzed using t-tests with Welch's correction. Sub-group analyses were performed to address data heterogeneity. Results: 5550 patients from 34 studies were included. The median age was 33.07 years, and 58.3% (n=3325) of the patients were male. The most common mechanism of injury was falling (n=3595, 67.3%). Injured patients were more likely to not have been wearing a helmet at the time of injury (70.3%, p<0.001). The most common type of injury incurred were bony injuries (n=2761, 40.2%), of which, the most common fracture location was the upper extremity (n=1236, 44.8%). Head and neck injuries composed 22.2% of the reported injuries, which included traumatic brain injuries (2.5%), lacerations/abrasions/contusions (7.1%), intracerebral brain hemorrhages (1.9%), and concussions (3.2%). Standard radiographs were the most common mode of imaging utilized (n=2153, 57.7%). Most patients were treated and released without admission (n= 2895, 52.2%), and 16.4% of injured patients required surgery. Qualitative analyses of the cost of injury revealed that any intoxication was associated with higher billing costs. Conclusion: Upper extremities fractures were the most common injury type incurred from e-scooter use, and the most common demographics were white, males in their early 30s. There should be more emphasis on wearing protective gear like wrist and elbow guards in addition to helmets. Future prospective studies with larger cohorts across multiple regions and hospitals are necessary to truly characterize the nature and cost of electric scooter injuries.
Kruppel-like factor 1–GATA1 fusion protein improves the sickle cell disease phenotype in mice both in vitro and in vivo
Authors: Zhu Jianqiong , Li Hongzhen , Aerbajinai Wulin , Kumkhaek Chutima , Pirooznia Mehdi , Saxena Ankit , Dagur Pradeep , Chin Kyung , Rodgers Griffin P. 
Published: November 2022

AbstractSickle cell disease (SCD) and β-thalassemia are among the most common genetic disorders worldwide, affecting global health and mortality. Hemoglobin A2 (HbA2, α2δ2) is expressed at a low level in adult blood due to the lack of the Kruppel-like factor 1 (KLF1) binding motif in the δ-globin promoter region. However, HbA2 is fully functional as an oxygen transporter, and could be a valid antisickling agent in SCD, as well as a substitute for hemoglobin A in β-thalassemia. We have previously demonstrated that KLF1-GATA1 fusion protein could interact with the δ-globin promoter and increase δ-globin expression in human primary CD34+ cells. We report the effects of 2 KLF1-GATA1 fusion proteins on hemoglobin expression, as well as SCD phenotypic correction in vitro and in vivo. Forced expression of KLF1-GATA1 fusion protein enhanced δ-globin gene and HbA2 expression, as well as reduced hypoxia-related sickling, in erythroid cells cultured from both human sickle CD34+ cells and SCD mouse hematopoietic stem cells (HSCs). The fusion proteins had no impact on erythroid cell differentiation, proliferation, and enucleation. Transplantation of highly purified SCD mouse HSCs expressing KLF1-GATA1 fusion protein into SCD mice lessened the severity of the anemia, reduced the sickling of red blood cells, improved SCD-related pathological alterations in spleen, kidney, and liver, and restored urine-concentrating ability in recipient mice. Taken together, these results indicate that the use of KLF1-GATA1 fusion constructs may represent a new gene therapy approach for hemoglobinopathies.
North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need
Authors: Pemmaraju Naveen , Kantarjian Hagop , Sweet Kendra , Wang Eunice , Senapati Jayastu , Wilson Nathaniel R. , Konopleva Marina , Frankel Arthur E. , Gupta Vikas , Mesa Ruben , Ulrickson Matthew , Gorak Edward , Bhatia Sumeet , Budak-Alpdogan Tulin , Mason James , Garcia-Romero Maria Teresa , Lopez-Santiago Norma , Cesarman-Maus Gabriela , Vachhani Pankit , Lee Sangmin , Bhatt Vijaya Raj , Blum William , Walter Roland B. , Bixby Dale , Gojo Ivana , Duvic Madeleine , Rampal Raajit K. , de Lima Marcos , Foran James , Fathi Amir T. , Hall Aric Cameron , Jacoby Meagan A. , Lancet Jeffrey , Mannis Gabriel , Stein Anthony S. , Mims Alice , Rizzieri David , Olin Rebecca , Perl Alexander , Schiller Gary , Shami Paul , Stone Richard M. , Strickland Stephen , Wieduwilt Matthew J. , Daver Naval , Ravandi Farhad , Vasu Sumithira , Guzman Monica , Roboz Gail J. , Khoury Joseph , Qazilbash Muzaffar , Aung Phyu P. , Cuglievan Branko , Madanat Yazan , Kharfan-Dabaja Mohamed A. , Pawlowska Anna , Taylor Justin , Tallman Martin , Dhakal Prajwal , Lane Andrew A. 
Published: November 2022

Abstract
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy with historically poor outcomes and no worldwide consensus treatment approach. Unique among most hematologic malignancies for its frequent cutaneous involvement, BPDCN can also invade other extramedullary compartments, including the central nervous system. Generally affecting older adults, many patients are unfit to receive intensive chemotherapy, and although hematopoietic stem cell transplantation is preferred for younger, fit individuals, not all are eligible. One recent therapeutic breakthrough is that all BPDCNs express CD123 (IL3Rα) and that this accessible surface marker can be pharmacologically targeted. The first-in-class agent for BPDCN, tagraxofusp, which targets CD123, was approved in December 2018 in the United States for patients with BPDCN aged ≥2 years. Despite favorable response rates in the frontline setting, many patients still relapse in the setting of monotherapy, and outcomes in patients with relapsed/refractory BPDCN remain dismal. Therefore, novel approaches targeting both CD123 and other targets are actively being investigated. To begin to formally address the state of the field, we formed a new collaborative initiative, the North American BPDCN Consortium (NABC). This group of experts, which includes a multidisciplinary panel of hematologists/oncologists, hematopoietic stem cell transplant physicians, pathologists, dermatologists, and pediatric oncologists, was tasked with defining the current standard of care in the field and identifying the most important research questions and future directions in BPDCN. The position findings of the NABC’s inaugural meetings are presented herein.
CircRNA AFF4 induced by KDM1A promotes osteogenic differentiation through FNDC5/Irisin pathway
Authors: Liu Ansong , Chen Yong , Zhong Da , Wang Chenggong , Yu Mi , Liu Chao , Yang Zhijun , Chen Wenkang , Yin Ke 
Published: November 2022

Abstract
Background
Circular RNA (circ) AFF4 was documented to regulate osteogenesis but the underlying mechanism remains to be elucidated. The preliminary study showed that circ_AFF4 may promote osteogenesis via FNDC5/Irisin. Furthermore, the online prediction tool indicated the interaction of circ_AFF4, insulin-like growth factor-2 mRNA-binding protein 3 (IGF2BP3), FNDC5 and lysine (K)-specific demethylase 1 A (KDM1A). Therefore, this study aims to elucidate the relationships of KDM1A, circ_AFF4, IGF2BP3 and FNDC5/Irisin during osteogenesis.

Methods
The alkaline phosphatase (ALP) activities and osteogenic-related factors were determined using ALP and alizarin red S (ARS) staining, real-time quantitative PCR(RT-qPCR) and western blot. Immunoprecipitation (RIP), pull-down assay and fluorescence in situ hybridization (FISH) were used to examine the interactions among circ_AFF4/IGF2BP3/FNDC5. A mouse in vivo model was utilized to further confirm the regulatory effect on bone formation.

Results
Circ_AFF4 and KDM1A expression levels were increased during osteoinduction of BM-MSCs. Knockdown of circ_AFF4 and KDM1A significantly suppressed BM-MSC osteogenesis. We also proved that KDM1A directly bound to circ_AFF4 and FNDC5 promoter and induced circ_AFF4 and FNDC5 expression. Furthermore, circ_AFF4 enhanced the stability of FNDC5 by generating a circ_AFF4, IGF2BP3 and FNDC5 RNA-protein complex, and thereby induced Irisin and osteogenesis. The in vitro data was confirmed with in vivo model.

Conclusion
These findings elucidate that KDM1A induces circ_AFF4, which promotes promote osteogenesis via IGF2BP3. This study indicates that circ_AFF4 may potentially represent a critical therapeutic target for the diseases.
Swiss QUality of life and healthcare impact Assessment in a Real-world Erenumab treated migraine population (SQUARE study): interim results
Authors: Gantenbein Andreas R. , Agosti Reto , Kamm Christian P. , Landmann Gunther , Meier Niklaus , Merki-Feld Gabriele Susanne , Petersen Jens A. , Pohl Heiko , Ryvlin Philippe , Schankin Christoph J. , Viceic Dragana , Zecca Chiara , Schäfer Elisabeth , Meyer Ina , Arzt Michael E. 
Published: November 2022

Abstract
Background
The fully human monoclonal antibody erenumab, which targets the calcitonin gene-related peptide (CGRP) receptor, was licensed in Switzerland in July 2018 for the prophylactic treatment of migraine.
To complement findings from the pivotal program, this observational study was designed to collect and evaluate clinical data on the impact of erenumab on several endpoints, such as quality of life, migraine-related impairment and treatment satisfaction in a real-world setting.

Methods
An interim analysis was conducted after all patients completed 6 months of erenumab treatment. Patients kept a headache diary and completed questionnaires at follow up visits. The overall study duration comprises 24 months.

Results
In total, 172 adults with chronic or episodic migraine from 19 different sites across Switzerland were enrolled to receive erenumab every 4 weeks. At baseline, patients had 16.6 ± 7.2 monthly migraine days (MMD) and 11.6 ± 7.0 acute migraine-specific medication days per month. After 6 months, erenumab treatment reduced Headache Impact Test (HIT-6™) scores by 7.7 ± 8.4 (p < 0.001), the modified Migraine Disability Assessment (mMIDAS) by 14.1 ± 17.8 (p < 0.001), MMD by 7.6 ± 7.0 (p < 0.001) and acute migraine-specific medication days per month by 6.6 ± 5.4 (p < 0.001). Erenumab also reduced the impact of migraine on social and family life, as evidenced by a reduction of Impact of Migraine on Partners and Adolescent Children (IMPAC) scores by 6.1 ± 6.7 (p < 0.001). Patients reported a mean effectiveness of 67.1, convenience of 82.4 and global satisfaction of 72.4 in the Treatment Satisfaction Questionnaire for Medication (TSQM-9). In total, 99 adverse events (AE) and 12 serious adverse events (SAE) were observed in 62 and 11 patients, respectively. All SAE were regarded as not related to the study medication.

Conclusions
Overall quality of life improved and treatment satisfaction was rated high with erenumab treatment in real-world clinical practice. In addition, the reported impact of migraine on spouses and children of patients was reduced.

Trial registration
BASEC ID 2018–02,375 in the Register of All Projects in Switzerland (RAPS).

Graphical Abstract
Comment regarding: what is the efficacy of aerobic exercise versus strength training in the treatment of migraine? A systematic review and network meta‑analysis of clinical trials
Authors: Han Junhee , Cho Soo-Jin 
Published: November 2022

AbstractIn Woldeamanuel and Oliveira (2022)’s article about the efficacy of exercise in the treatment of migraine, the ranking of the efficacy of strength training (mean difference, − 3.55), aerobic exercise (mean difference, − 2.18 to − 3.13), topiramate (mean difference, − 0.98), and amitriptyline (mean difference, 3.82) using network meta-analysis can mislead readers. First, the inclusion criteria were reported at a monthly frequency of migraine and the end of the intervention, but some article did not meet the inclusion criteria or had data inconsistency. Second, there was an inconsistency in the placebos used in the included studies, which can be problematic in network meta-analysis. Third, all three articles on strength training were rated as high-risk or exhibited some risk of bias. Finally, the effectiveness of this statistical method is questionable for assessing physical activities because strength training, aerobic exercise, and preventive medications can be simultaneously recommended for possible synergistic effects in the prevention of migraine.
Developing a clinical decision tool based on electroretinogram to monitor the risk of severe mental illness
Authors: Peredo Rossana , Hébert Marc , Mérette Chantal 
Published: November 2022

Abstract
Background
We have shown that electroretinograms can discriminate between patients with severe mental illness (SMI) and healthy controls in previous studies. We now intend to enhance the development and clinical utility of ERG as a biological tool to monitor the risk of SMI.

Methodology
A sample of 301 SMI patients (bipolar disorder or schizophrenia) and 200 controls was first split into a training (N = 401) and testing dataset (N = 100). A logistic regression using ERG was modeled in the training data, while external validation and discriminative ability were assessed in the testing data. A decision curve analysis was used to test clinical usefulness. Moreover, the identification of thresholds of uncertainty based on the two-graph ROC and the interval of uncertainty was used to enhance prediction.

Results
The discriminative assessment of the ERG showed very high sensitivity (91%) and specificity (89%) after considering uncertainty levels. Furthermore, for prediction probabilities ranging from 0.14 to 0.95 in the testing data, the net benefit of using our ERG model to decide whether to intervene or not exceeded that of never or always intervening.

Conclusion
The ERG predicted SMI risk with a high level of accuracy when uncertainty was accounted for. This study further supports the potential of ERG to become a useful clinical decision tool to decide the course of action for subjects at risk of SMI. However, further investigation is still needed in longitudinal studies to assess the external validity of the instrument.
Wealth disparity and frailty among community-dwelling older adults in India
Authors: Saravanakumar Priya , Balachandran Arun , Muhammad T. , Drishti Drishti , Srivastava Shobhit 
Published: November 2022

Abstract
Background
Due to the vast socioeconomic diversity among its residents, studying health inequality in India is of particular interest. This study aimed to investigate the wealth-based inequalities in physical frailty and to quantify the contributions of potential predictors of frailty to this inequality.

Methods
Data were drawn from the first wave of the Longitudinal Ageing Study in India (LASI) conducted during 2017–18. Logistic regression analysis was used to examine the association between wealth status and frailty. We used the concentration index to measure the magnitude of wealth-related inequality in frailty. A decomposition analysis based on the logit model was used to assess the contribution of each predictor to the total inequality.

Results
The prevalence of physical frailty was significantly higher among the older adults in the poor group than in the non-poor group [Difference (poor vs. non-poor): 6.4%; p < 0.001]. Regression results indicated that older adults in the poorest group were 23% more likely to be physically frail than those in the richest category [Adjusted odds ratio (AOR) = 1.23; 95% confidence interval (CI): 1.11, 1.38]. The overall concentration index of frailty was 0.058 among the older adults, indicating that frailty is more concentrated among older adults with poor wealth status. Body mass index, wealth index, educational status, and region were the major and significant contributors to the socioeconomic status (SES) related inequalities in frailty.

Conclusions
Results suggest the need for formulating effective prevention and intervention strategies to decelerate the development of physical frailty among older adults in India, especially those with poor socioeconomic background.